Lenz Robert A. has filed 15 insider transactions across 2 companies since September 2023.
Most recent transaction: a grant/award of 20000 shares of LB PHARMACEUTICALS INC ($LBRX) on March 06, 2026.
Activity breakdown: 0 open-market purchases and 6 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | LB PHARMACEUTICALS INC | $LBRX | Lenz Robert A. | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 25,299,102 | 9999.99% | 0.08% |
| Feb. 18, 2025 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 5614 | $1.67 | 309,092.0000 | 0 | 1.78% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | D | Stock Option (Right to Buy) | 100000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Stock Option (Right to Buy) | 502934 | $0.00 | 502,934.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | D | Stock Option (Right to Buy) | 502934 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 10, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 8260 | $15.09 | 314,706.0000 | 0 | 2.56% | 0.00% |
| Oct. 9, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 5563 | $15.01 | 322,966.0000 | 0 | 1.69% | 0.00% |
| Sept. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 10676 | $12.09 | 328,529.0000 | 0 | 3.15% | 0.00% |
| Sept. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 30788 | $11.81 | 339,205.0000 | 0 | 8.32% | 0.00% |
| Sept. 12, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | S | Common Stock | 32948 | $11.43 | 369,993.0000 | 0 | 8.18% | 0.00% |
| Feb. 14, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Common Stock | 50000 | $0.00 | 402,941.0000 | 0 | 14.17% | 0.00% |
| Sept. 14, 2023 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Stock Option (Right to Buy) | 502934 | $0.00 | 502,934.0000 | 0 | 9999.99% | 0.00% |
| Sept. 14, 2023 | Neumora Therapeutics, Inc. | $NMRA | Lenz Robert A. | Head of R&D | A | Common Stock | 352941 | $0.00 | 352,941.0000 | 0 | 9999.99% | 0.00% |